Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

. Additional clinical programs include the development of CCX140, which targets the CCR2 receptor, currently in a Phase I clinical trial and intended for subsequent development to treat diseases such as Type 2 diabetes, multiple sclerosis and vascular restenosis, and CCX354, a CCR1 antagonist in a Phase I clinical trial, being developed for inflammatory diseases such as rheumatoid arthritis. ChemoCentryx also has several programs in preclinical development. ChemoCentryx is privately held. For more information, please refer to www.chemocentryx.com.

Any statements in this press release about ChemoCentryx's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as may, believe, will, expect, anticipate, estimate, intend, predict, seek, potential, continue, plan, should, could and would or the negative of these terms or other comparable terminology. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections contained in the forward-looking statements include but are not limited to (i) the initiation, timing, progress and results of ChemoCentryx's preclinical studies and clinical trials, (ii) ChemoCentryx's ability to advance product candidates into clinical trials, (iii) GSK's exercise of its license options, (iv) the commercialization of ChemoCentryx's product candidates, (v) the implement
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... , July 11, 2014 /PRNewswire-iReach/ -- VAPETEK™, ... a vegetable-glycol solution for use in portable vaporizers, ... the active ingredients in cannabis, cannabidiol offers consumers ... vaporizer devices, and other vaporizer technology. ... Cannabis naturally contains 483 different compounds which are ...
(Date:7/11/2014)... CHAPEL HILL, N.C. , July 11, 2014 ... component of pharmaceutical marketing and, consequently, organizations are ... specifically for patients. As part of ... learned it,s important to educate, communicate and engage ... from disease awareness to patient empowerment. By mapping ...
(Date:7/11/2014)... July 11, 2014 The consumer marketing ... across industry sectors to better identify winning tools ... to engage with and understand consumers, as new ... make critical purchasing decisions. According ... LLC, one area where organizations can observe a ...
Breaking Medicine Technology:VAPETEK Releases CBD-Infused eLiquid For The Consumer Market 2New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2New Technologies Transforming Consumer Marketing Research Playbook 2
(Date:7/13/2014)... noninvasive optical imaging device developed at Cedars-Sinai can ... in the brain and are a classic sign ... investigators conducting a clinical trial in Australia. , ... in an oral presentation at the Alzheimer,s Association ... were invited by conference organizers to participate in ...
(Date:7/13/2014)... A Xarelto lawsuit webpage has ... provide consumers with the most current information regarding serious ... blood-thinning medication, as well as the growing number ... the country. The law firm is now offering free ... life-threatening internal bleeding and related complications while using Xarelto, ...
(Date:7/13/2014)... July 13, 2014 If Dr. Lawrence Power ... has just launched at http://www.HealthYourself101.com will expand people’s ... , Power has set out to provide a health ... that’s actually – dare we say it? – entertaining to ... Power, “aims to engage the remote learner – the solitary ...
(Date:7/12/2014)... 13, 2014 According to the new ... Systems, Airborne Systems, and Naval Systems) - Global Forecasts ... Security and Surveillance Radar market are estimated to be ... a CAGR of 5.97% to reach $8.61 billion by ... with 47 figures spread through 161 pages and in-depth ...
(Date:7/12/2014)... 12, 2014 The Passenger Information System ... 2013 to $20,341.36 million by 2019, at an expected ... 2019. , The public transport infrastructure in North America ... available in almost every corner of the region. The ... of public transport service providers are driving the North ...
Breaking Medicine News(10 mins):Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 2Health News:Study of noninvasive retinal imaging device presented at Alzheimer's conference 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 2Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 3Health News:Xeralto Lawsuit Page Launched By Wright & Schulte LLC To Provide Information On Potential For Xarelto Bleeding Side Effects, Growing Litigation 4Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 2Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 3Health News:Retired Ann Arbor Physician and Professor Wields New Media to Teach Health Science 4Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Security and Surveillance Radar Market Estimated to Reach $8.61 Billion by 2020 – New Report by MarketsandMarkets 4Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 2Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 3Health News:North America Passenger Information System (ICT) Market worth $5,486.88 Million by 2019 - New Report by MicroMarket Monitor 4
... the decline in lung function in patients with chronic ... the TORCH (TOwards a Revolution in COPD Health) study ... ,The study of 6,112 patients from 42 ... had a slower rate of lung function decline compared ...
... threatening to completely wipe out wild relatives of plants such ... by the Consultative Group on International Agricultural Research (CGIAR). ... years as many as 61 percent of the 51 wild ... potato species analyzed could become extinct as the result of ...
... Davis campuses of the University of California has found that ... free-floating virus. ,The researchers hope that this technique ... a pan of water over a flame or single burner ... developing nations will soon be able to more safely feed ...
... Recent research suggests that inhaling straight oxygen can harm the ... affects. ,Published in the edition ... in the face of national guidelines for medical practice and ... mix to preserve brain function in patients. ...
... rigorous U.S. trial comparing two traditional operations for stress ... urologists and urogynecologists supported by the National Institutes of ... more women achieve dryness than the Burch technique. ... a meticulous, relatively long-term comparison of these common surgeries ...
... A new study has revealed that women diagnosed with ... already exercise , then they should continue exercising, ... ,Ohio State University researchers analysed 500 women, who ... activity, and more specifically the intensity and amount of ...
Cached Medicine News:Health News:Drug Treatment Slows Decline in Lung Function in COPD Patients 2Health News:Climate Change Threatening to Wipe Out Wild Relatives of Key Crops 2Health News:Flash-heating Inactivates HIV in Breast Milk: Study 2Health News:Flash-heating Inactivates HIV in Breast Milk: Study 3Health News:UCLA Imaging Study Reveals How Pure Oxygen Harms the Brain 2Health News:UCLA Imaging Study Reveals How Pure Oxygen Harms the Brain 3Health News:Sling Surgery Better Than Burch for Treating Stress Incontinence in Women 2Health News:Sling Surgery Better Than Burch for Treating Stress Incontinence in Women 3Health News:Exercise may Help Breast Cancer Patients to Lead a Healthy Life 2
One channel transcranial Doppler...
Locates flow easily, and identifies flow depth and direction for multiple vessels simultaneously....
... an advanced Doppler system that allows non-invasive ... body. This method of measurement is particularly ... blood to the brain. , ,TCD is ... problems such as vasospasm and intracranial stenosis. ...
Swiss Watchmaker Forceps, 4" extra-long precision ground points....
Medicine Products: